Myelodysplastic Syndromes (MDS)

MDS and AML Research Summaries for Patience from the 2018 American Society of Hematology Annual Meeting

Research Summaries for Patients from the 2019 European Hematology Association and the 2019 American Society of Clinical Oncology meetings

Summary for patients from the seventh International Bone Marrow Failure Disease Scientific Symposium

MDS and AML Research Summaries for Patients from the 2021 European Hematology association and the American Society of Clinical Oncology Annual Meetings

MDS and AML Research Summaries for Patients from the 2020 European Hematology association and the American Society of Clinical Oncology Meetings

RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor used to treat adults with IPSS-R low to intermediate-1 myelodysplastic syndromes (MDS) with transfusion dependent anemia requiring four or more red blood…

TIBSOVO is a prescribed medication approved to treat adult patients with myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation either when the disease has relapsed or has not improved after…

REBLOZYL® (luspatercept-aamt) was the first erythroid maturation agent (EMA) approved in 2020 by the Food and Drug Administration for the treatment of anemia in adult patients with myelodysplastic syndromes (MDS) who…

INQOVI® (previously known as ASTX727) is a prescribed oral tablet combination of decitabine and cedazuridine approved by the Food and Drug Administration for adult patients with myelodysplastic syndromes (MDS) and…

Form to keep track of platelet transfusions as part of MDS treatment